PERSONALIZED MEDICINE—NEXT GENERATION
WITH THE SUPPORT OF STRATEGIC PARTNERSHIPS, A ROBUST RESEARCH INFRASTRUCTURE AND AN EXPANDING TEAM OF PEDIATRIC EXPERTS, PHOENIX CHILDREN’S IS POISED TO LEAD THE FIELD OF PEDIATRIC PERSONALIZED MEDICINE INTO THE FUTURE.
In the 15 years since the first targeted cancer therapy received Food and Drug Administration approval, the rapid growth in this area has been staggering. The ultimate goal is for every child to receive customized care based on the genetic and proteomic basis of the disease.
Already, many types of cancer can be attacked and destroyed by exploiting, confusing or otherwise targeting the molecular expression of cancer cells. These treatments undo the genetic mechanisms that make cancer cells grow uncontrollably and improve outcomes and cure rates even for advanced disease. But these solutions, especially in pediatric medicine, are coming too few and far between.
The solution is to make targeted therapy the standard of care, not the trial or the exception. Establishing the Chan Soon-Shiong Children’s Precision Medicine Institute at Phoenix Children’s Hospital provided the foundation to advance as a leader and innovator in personalized treatment, genomic medicine and one day, even a cure.
“Personalized medicine represents the future of pediatric care. This is not some unattainable ideal. It will be the standard of care here at Phoenix Children’s Hospital, and our patients will be the ones who benefit.”
Shooting for the moon
Finding answers to childhood diseases starts with better understanding of the enemy, and that requires data. The rarity of so many childhood cancers and other genetic conditions makes it difficult for a single institution to gather enough information to make a difference—even one with a high volume of specialized cases, like Phoenix Children’s.
Pursuing strength in numbers, Phoenix Children’s helped initiate the Cancer MoonShot 2020 Pediatrics Consortium, a group of leading children’s hospitals from across the country whose mission is to bring the next-generation standard of care and immunotherapy to pediatric cancer patients. For the first time, an alliance of hospitals, pharmaceutical and biotech companies, insurers, research institutions, and technology innovators are coming together as a unified front to accelerate genomic and translational research into therapies more quickly and effectively than ever before.
Leading the way
Phoenix Children’s will serve as the pediatric hub of the Cancer MoonShot 2020 program. The necessary infrastructure is already in place:
- College of American Pathologists (CAP) accredited the Phoenix Children’s Biospecimen Laboratory
- CLIA-certified Lab will offer whole genome sequencing, RNA sequencing and proteomics
- A High Performance Computing Platform to offer high throughput, complex genomic analysis to researchers across the country
- Direct high speed fiber connection to the Nant Genomic Testing Facility in Culver City, California, for rapid transfer of genomic data
- Comprehensive cancer population management platform, designed not just to collect and analyze clinical data, but to drive new models of clinical management and save patient lives
genomic-based treatment for all patients
Today and in the future, personalized medicine will continue to be incorporated into the care of children with cancer as well as other diseases. As Phoenix Children’s changes the world of pediatric care, personalized medicine will not be reserved for a select few; genomic screening will be available to all children under the care of a Phoenix Children’s provider.
Our vision will be reality very soon: genetic counseling will help identify children who are more highly prone to pediatric diseases. Oncologists, cardiologists, neurologists and other experts will weave this data into the standard of care they provide.